Navigation Links
Lexicon's IBS Drug Candidate, LX1033, Successfully Completes Phase 1 Clinical Trial
Date:7/28/2011

randomized, placebo-controlled trial in healthy volunteers.  In the multiple ascending dose portion of the study, doses of 250 mg, 500 mg, and 750 mg given three times daily, as well as 1,000 mg given twice daily, were administered over the course of 14 days.  There were eight healthy volunteers (six receiving active compound, two receiving placebo) in each dose group.  Study endpoints included safety and tolerability together with pharmacokinetic and pharmacodynamic parameters consisting of measures of both plasma and urinary 5-HIAA.  Data from the study showed that LX1033 produced a statistically significant decrease in both plasma and urinary 5-HIAA as compared to placebo at all doses tested.  Notably, the plasma measures of 5-HIAA in the recent study were obtained from a simple morning blood draw and correlated with results obtained by the traditional 24-hour urine collection method.

"The favorable safety and tolerability profile for LX1033, together with its local site of action within the gastrointestinal tract and ability to potently reduce serotonin synthesis, make this a very attractive candidate for clinical trials in IBS-d, where the need for new treatments is great," said Dr. Pablo Lapuerta, senior vice president and chief medical officer at Lexicon.  "We look forward to advancing this drug into a Phase 2 trial where we can examine safety and efficacy in IBS-d."

About LX1033

LX1033 is an orally-delivered drug candidate for IBS that inhibits tryptophan hydroxylase (TPH), a key enzyme in the synthesis of serotonin.  LX1033 is designed to act locally in the gastrointestinal (GI) tract by reducing the serotonin available for receptor activation, without affecting serotonin levels in the brain.  

About Lexicon

Lexicon is a biopharmaceutical company focused on discovering breakthrough treatments for human diseas
'/>"/>

SOURCE Lexicon Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Polaris Group to Highlight Clinical Development Plans for Phase 3-Ready Candidate, ADI-PEG 20, During Symposium in Taiwan
2. Cardioxyl Pharmaceuticals Presents Data On Its Clinical Candidate, CXL-1020, at the 60th Annual American College of Cardiology Scientific Session
3. Cardioxyl Pharmaceuticals Initiates Dose-Defining Phase IIa Study of Its Lead Candidate, CXL-1020, in Heart Failure Patients
4. Arcion Therapeutics Topical Gel Candidate, ARC-4558, Demonstrates Significant Pain Reduction in Phase 2b Trial for Painful Diabetic Neuropathy (PDN)
5. Regado Biosciences, Inc. Introduces REG2, Its Second Product Candidate, at the American College of Cardiology Conference, 59th Annual Scientific Session, in Atlanta, Georgia on March 15, 2010
6. Orexigen(R) Therapeutics Schedules September 30, 2009 Teleconference and Webcast to Discuss Phase 2b Trial Results From Second Obesity Drug Candidate, Empatic(TM)
7. Proteolix, Inc. Drug Candidate, PR-957, Prevents Disease Progression in Rheumatoid Arthritis Models by Selective Inhibition of the Immunoproteasome
8. Arcion Therapeutics Topical Pain Candidate, ARC-4558, Significantly Reduces Pain Caused by Diabetic Neuropathy
9. NovaBay Pharmaceuticals Announces Lead Anti-infective Product Candidate, NVC-422, Shown to be Effective in Treating Topical Fungal Infection
10. Bionovo Announces Development Plans for Menopausal Hot Flash Drug Candidate, Menerba (MF101), Following FDA Meetings
11. Ardea Biosciences Presents Phase 2a Antiviral Activity Data for Lead HIV Candidate, RDEA806 at XVII International AIDS Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... Sept. 23, 2014   LabStyle Innovations Corp ... Management Solution, today announced that it has closed ... shares of preferred stock and warrants.  No placement ... offering expenses, LabStyle expects to secure net proceeds ... LabStyle intends to use the net ...
(Date:9/23/2014)... , September 23, 2014 ... améliorée lors d,une série de démonstrations personnelles   ... dans le domaine de l,analyse de la ... au stand n° 1035 lors de la réunion ... San Diego , en Californie. FDNA ...
(Date:9/23/2014)... , Sept. 23, 2014 Report Details ... showing you trends, R&D and predicted revenues Do ... inhibitors? Now get the latest analysis for those ... results, opportunities and revenue forecasts. Visiongain,s new ... protein kinase inhibition and related technology. There avoid ...
Breaking Medicine Technology:LabStyle Innovations Closes $4.2 Million Non-Brokered Private Placement Financing 2LabStyle Innovations Closes $4.2 Million Non-Brokered Private Placement Financing 3LabStyle Innovations Closes $4.2 Million Non-Brokered Private Placement Financing 4LabStyle Innovations Closes $4.2 Million Non-Brokered Private Placement Financing 5FDNA exposera sa solution Face2Gene intégrée en ligne avec London Medical Databases (LMD) à l'ASHG 2014 2FDNA exposera sa solution Face2Gene intégrée en ligne avec London Medical Databases (LMD) à l'ASHG 2014 3Kinase Inhibitors for Treating Cancer: Industry Analysis, R&D Trends and World Market Forecasts 2014-2024 2Kinase Inhibitors for Treating Cancer: Industry Analysis, R&D Trends and World Market Forecasts 2014-2024 3Kinase Inhibitors for Treating Cancer: Industry Analysis, R&D Trends and World Market Forecasts 2014-2024 4Kinase Inhibitors for Treating Cancer: Industry Analysis, R&D Trends and World Market Forecasts 2014-2024 5
... 22, 2011 /PRNewswire-Asia/ -- China Health Resource, Inc. (OTCBB: ... (TCM) products, announced robust record breaking quarterly earnings for ... and $1.8 million in net income, a 219% increase ... the third quarter of 2010. This translates to earnings ...
... HILL, N.C., Nov. 21, 2011  In today,s payer-driven market, ... of a new pharmaceutical product. However, sustaining commercial success ... processes that will increase market share after the product ... of practices to manage the challenges of the pull-through ...
Cached Medicine Technology:China Health Resource Announces Record Breaking 3rd Quarter 2011 Financial Results 2China Health Resource Announces Record Breaking 3rd Quarter 2011 Financial Results 3Managed Care Pull-Through Programs Target Physicians, Boost Market Share 2
(Date:9/23/2014)... (PRWEB) September 23, 2014 "The primary purpose ... control," said an inventor from Sacramento, Ca.. "Call lights are ... or left hanging on the IV pole out of the ... the nurse call device whenever they need it, I created ... effectively position the nurse call device within easy reach. The ...
(Date:9/23/2014)... Davis, and Academia Sinica, the preeminent academic institution ... into a collaborative agreement to develop a unique ... research with opportunities to translate innovative technologies and ... agreement was signed Sept.12 in Taipei by Harris ... and President Chi-Huey Wong of Academia Sinica. The ...
(Date:9/23/2014)... (PRWEB) September 23, 2014 AttorneyOne.com, a ... all the latest information from the FDA on ... 5, that its Private Label Jalapeno Bagels are recalled ... stones. Publix Jalapeno Bagels were sold in ... department. , Taking into consideration the latest developments, ...
(Date:9/23/2014)... Kathleen Doheny HealthDay Reporter ... at very low birth weights, breast milk is more likely ... infection known as cytomegalovirus (CMV), a new study finds. ... infants -- all of whom weighed 3.3 pounds or less ... of CMV infection, to see whether breast milk or transfusions ...
(Date:9/23/2014)... 2014 (HealthDay News) -- Both drinking and getting drunk ... alcohol abuse by high school students, a new study ... high school students who drink, could help expand alcohol-prevention ... drink, to stop them from becoming binge drinkers, the ... of first alcohol use and progression to first heavy ...
Breaking Medicine News(10 mins):Health News:Academia Sinica, UC Davis sign agreement on exchanges and tech transfer 2Health News:Publix Private Label Jalapeno Bagels Recalled: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Breast Milk a Risk for Spreading Common Virus to Preemies, Study Finds 2Health News:Breast Milk a Risk for Spreading Common Virus to Preemies, Study Finds 3Health News:Younger Age at First Drink, Higher Odds for Problem Drinking: Study 2Health News:Younger Age at First Drink, Higher Odds for Problem Drinking: Study 3
... Reactors Could Solve the Isotope Crisis within 24 months ... Nordion, a leading provider of medical isotopes and radiopharmaceuticals, ... Expert Review Panel on Medical Isotope and Technetium-99m (Tc-99m) ... to the shortage of medical radioisotopes is the completion ...
... male and seven female) with hepatic angiomyolipoma, with a ... Of these patients, dynamic contrast CT showed hepatic angiomyolipoma ... of a capsule, and prominent central vessels in six ... without a fat component in four cases with tuberous ...
... , DENVER July 30 Air Methods Corporation ... quarter ended June 30, 2009 after the close of the market on ... for Thursday, August 6, 2009 at 4:15 p.m. Eastern to discuss these ... the call by dialing (877) 883-0656 (domestic) or (706) 643-8826 (international) or ...
... , PLEASANTON, Calif., July 30 TriReme ... second product, a novel coronary dilatation catheter, designed to improve ... near side branches. The product will be marketed under the ... a first-in-class balloon dilatation catheter with a torquable shaft and ...
... centers didn,t increase weight, study found , THURSDAY, July 30 ... else,s home, they,re more likely to be heavier than average ... researchers report in the August issue of Pediatrics ... for in someone else,s home, rather than in their own ...
... WILMINGTON, Del., July 30 AstraZeneca (NYSE: ... a New Drug Application to the U.S. Food and Drug ... European Medicines Agency (EMEA) for an investigational drug, vandetanib 100 ... of advanced non-small cell lung cancer in patients previously treated ...
Cached Medicine News:Health News:MDS Nordion Submits Expression of Interest Proposal to Government of Canada on Medical Isotope and Generator Production 2Health News:MDS Nordion Submits Expression of Interest Proposal to Government of Canada on Medical Isotope and Generator Production 3Health News:TriReme Medical, Inc. Receives CE Marking for Glider(TM) PTCA Dilatation Catheter 2Health News:Infants Cared for in Another Home Become Heavier Toddlers 2Health News:Infants Cared for in Another Home Become Heavier Toddlers 3Health News:AstraZeneca Submits New Drug Applications for ZACTIMA(TM) in Second-Line Advanced Non-Small Cell Lung Cancer 2Health News:AstraZeneca Submits New Drug Applications for ZACTIMA(TM) in Second-Line Advanced Non-Small Cell Lung Cancer 3Health News:AstraZeneca Submits New Drug Applications for ZACTIMA(TM) in Second-Line Advanced Non-Small Cell Lung Cancer 4
... ALLEGRO Topolyzer and T-CAT have been optimized ... vision correction and to interact in perfect ... systems. All necessary treatment and patient parameters ... the ALLEGRETTO WAVE laser systems via diskette, ...
RESTASIS® (cyclosporine ophthalmic emulsion) 0.05% is the first and only therapy for patients with keratoconjunctivitis sicca (Dry Eye Disease) whose tear production is presumed to be supressed d...
ZYMAR™ ophthalmic solution is an anti-infective prescription eye drop that your doctor may instruct you to use if you have an eye infection caused by bacteria. Bacterial conjunctivitis is the e...
... P.M.® lets you sleep on ... in the morning awake with ... ready to take on the ... comfort and protection, this preservative-free ...
Medicine Products: